London, April 22, 2026, 19:09 BST
GSK plc picked up 335,000 ordinary shares on Tuesday, according to a U.S. securities filing, as the company’s buyback program heads toward its planned end just ahead of next week’s earnings report. BNP Paribas handled the trades, paying between 2,074p and 2,130p per share; the volume-weighted average came in at 2,103.08p. These shares, bought for treasury, stay off the public voting tally, though they remain in GSK’s hands.
The timing’s key here. GSK expects to wrap up the fourth tranche of its buyback by April 24. First-quarter results land at 0700 BST on April 29. Sure, buybacks help lift earnings per share by cutting the share count, but investors aren’t just watching that—they want clearer evidence of sales picking up.
Investors barely budged on GSK’s fresh buyback: shares slipped another 0.34% to 2,075p in London on Wednesday, after a sharper 2.89% drop the previous session. The FTSE 100 finished the day down 0.21%.
As of April 16, company-gathered analyst consensus pegs first-quarter turnover at 7.58 billion pounds: Specialty Medicines delivers 3.23 billion, Vaccines lands at 2.03 billion, and General Medicines rounds out with 2.32 billion. Looking ahead to 2026, GSK is targeting turnover growth in the 3% to 5% range at constant exchange rates, with core EPS expected to climb between 7% and 9%.
Luke Miels stepped in as Chief Executive back in January and isn’t pitching 2026 as another overhaul year—he’s calling it an execution play. In February, Miels told reporters GSK must “accelerate what we have” and look for ways to grow via “smart business development.” Sheena Berry, a healthcare analyst with Quilter Cheviot, described his outlook as a “steady and credible start.” Reuters
The outlook remains divided. Back in February, Jefferies’ Michael Leuchten flagged a “4Q Sales 2% beat,” but pointed out that management guidance hinted at consensus downgrades ahead, thanks to FX headwinds. Over at Hargreaves Lansdown, Derren Nathan said GSK was “brimming with pipeline catalysts,” though he noted some key milestones have been pushed out on the calendar. Investing
Product updates have kept the spotlight on GSK’s drug pipeline. The company announced Monday that China’s regulators cleared Blenrep, combined with bortezomib and dexamethasone, for adults battling relapsed or refractory multiple myeloma after at least one earlier treatment. Hesham Abdullah, who heads global oncology R&D at GSK, said the decision gives Chinese patients access to anti-BCMA therapy — a treatment that targets the B-cell maturation antigen on myeloma cells.
The company is putting money behind an expansion of its respiratory and immunology portfolio. Just last week, GSK wrapped up its $950 million purchase of 35Pharma, picking up HS235—an early-stage drug candidate for pulmonary hypertension. That’s high blood pressure affecting the lungs. GSK’s Kaivan Khavandi called HS235 “an important addition” to the pipeline, which targets chronic inflammatory and fibrotic diseases. GSK
Competition isn’t letting up. Reuters points out that Merck’s injectable Winrevair is already among the therapies used for pulmonary hypertension. Over in respiratory diseases, GSK’s Nucala faces established rivals—Sanofi and Regeneron’s Dupixent, for example, is cleared for chronic obstructive pulmonary disease, a lung disorder marked by airflow limitation.
But there’s a ceiling on the buyback. GSK has flagged that foreign exchange could drag down first-quarter sales by 3% to 4%, and says R&D outlays will outpace sales growth as it pours money into its pipeline. Should currency swings worsen, vaccine appetite cool, or early-stage programs like HS235 stall, snapping up shares might not deliver enough of a per-share boost to sway the market’s stance.
That puts extra pressure on next week’s results, which matter more than Wednesday’s filing. Investors want to see Miels deliver: capital returns, new drug approvals, and bolt-on acquisitions all pushing forward together. If not, the buyback may start looking like a safety net rather than a spark.
